$220.00
RT30 is a novel investigational drug developed to treat obesity and metabolic disorders by targeting three hormone pathways: GLP-1, GIP, and glucagon receptors. This triple agonist helps regulate appetite, enhance insulin sensitivity, and boost energy expenditure, leading to substantial and sustained weight loss. Early clinical studies show superior results compared to current weight-loss therapies, with additional benefits for liver function, blood sugar control, and cardiovascular markers.
Administered as a once-weekly injection, RT is being explored as a powerful tool for managing obesity, type 2 diabetes, and related conditions. It remains under clinical investigation and is not yet FDA-approved.
RT30 is a next-generation investigational drug designed to support significant weight loss and improve metabolic health. It’s a triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors—three key pathways that regulate appetite, energy use, and blood sugar levels.
In clinical trials, RT30 has shown unprecedented results in helping adults with obesity or overweight conditions reduce body weight, potentially beyond what’s been seen with current GLP-1 drugs. By combining multiple metabolic signals into one therapy, it offers a powerful, multi-faceted approach to managing obesity, type 2 diabetes, and related conditions.
These ranges are general, research-use suggestions to help you prepare your peptides. This calculator and recommended doses are not medical advice. Start low, assess tolerance, and adjust cautiously.
Dynamic Peptides supplements – transform your body and elevate your health. These compounds are made from the highest quality ingredients that promote overall wellness, improves performance, and contributes to a longer, more vibrant life. Our peptides provide a comprehensive approach to health and fitness, boosting muscle growth, speeding recovery, and enhancing mental sharpness.
A next-gen metabolic peptide positioned for aggressive appetite and body-composition research outcomes.
Elite cutting-phase positioning; Targets appetite/metabolic pathways; Advanced protocol staple.
Dynamic Peptides is your go-to spot for peptides made with the purest and finest ingredients as we strive and maintain our reputation for delivering the highest quality products in all of North America. Experience the difference when it comes to our dedication to excellence, providing the best customer service possible, and our products are supported by rigorous quality controls ensuring pharmaceutical-grade quality.
RT30 is an investigational once-weekly injectable drug designed to treat obesity and related metabolic conditions. For lab research only.
RT30 may cause gastrointestinal symptoms including nausea, vomiting, diarrhea, or constipation, particularly during dose escalation. Some users report appetite suppression that may lead to inadequate caloric intake. Other potential side effects include fatigue, abdominal discomfort, and injection site irritation.
Hypoglycemia is rare but possible when used with other glucose-lowering medications. Rapid weight loss may increase the risk of gallstones. Clinical monitoring is advised, especially for those with a history of pancreatitis or thyroid disorders. While early results are promising, long-term safety and efficacy are still under investigation. Patients should only use RT30 under medical supervision during ongoing trials.
RT30 is administered via subcutaneous injection once weekly, typically in the abdomen or thigh. Initial doses start low and are gradually increased to minimize gastrointestinal side effects. In clinical trials, the dosage is titrated over several weeks up to 12 mg weekly, depending on tolerance and patient response.
Injections should be taken on the same day each week, with or without food. Missed doses should be taken within 4 days; otherwise, skip and resume the regular schedule. Patients should monitor for nausea, appetite suppression, or signs of dehydration, and stay hydrated. RT30 is investigational and must be used under medical supervision.
There are no reviews yet.